Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BICALUTAMIDE

All products: general benefit

Other products in the same Health Canada class (L02B, L02BB) — coverage varies; not interchangeable

  • Flutamide (Euflex): general benefit, Not a benefit
  • Enzalutamide (Xtandi): not a benefit
  • Abiraterone (Zytiga): general benefit
  • Anastrozole (Arimidex): general benefit
  • Degarelix (Firmagon): general benefit
  • Exemestane (Aromasin): general benefit

3 more in the class list below

Co Bicalutamide · DIN 02274337 · 50mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.Discontinued 2018-07-11 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Bicalutamide · DIN 02274337 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2006-04-04 Health Canada: Cancelled post market since 2018-07-11 · brand ACT BICALUTAMIDE · ATC L02BB03 BICALUTAMIDE · form Tablet · route Oral · ingredients BICALUTAMIDE 50 MG · company Actavis pharma company · schedule Prescription
Check this DIN again · Health Canada product record

Co Bicalutamide: Formulary list price $1.2690/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2690 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75978 · Verify on the e-Formulary ↗ (DIN 02274337)

Source record
DIN 02274337: Co Bicalutamide Raw flags: sec3=Y Item: 100000108; group id 145; item number 0244; lccId None; manufacturer id COB Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.2690; ministry $1.2690 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02274337 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75978
Interchangeable products
Apo-Bicalutamide · DIN 02296063 · $1.2690 Bicalutamide · DIN 02519178 · $1.2690 Bicalutamide Tablets · DIN 02325985 · $1.2690 Casodex · DIN 02184478 · not recorded Jamp-Bicalutamide · DIN 02357216 · $1.2690 PMS-Bicalutamide · DIN 02275589 · $1.2690 Ran-Bicalutamide · DIN 02371324 · $1.2690 Teva-Bicalutamide · DIN 02270226 · $1.2690
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2018-07-11 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

FLUTAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ENZALUTAMIDE

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

DEGARELIX ACETATE

· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk

EXEMESTANE

· 3 products · General benefit · strengths: 25mg · Tab

FULVESTRANT

· 6 products · General benefit · strengths: 50mg/mL · Inj Sol

LETROZOLE

· 20 products · General benefit · strengths: 2.5mg · Tab

TAMOXIFEN CITRATE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-BICALUTAMIDE (bicalutamide) 50 mg is indicated for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer. Pediatrics: The safety and effectiveness of bicalutamide in children has not been established. https://pdf.hres.ca/dpd_pm/00041652.PDF PM date: September 27, 2017 Source product: TEVA-BICALUTAMIDE; DIN 02270226; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.